Syndax Pharmaceuticals Stock Forecast, Price & News

-1.58 (-8.22 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume365,819 shs
Average Volume760,352 shs
Market Capitalization$851.59 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SNDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Syndax Pharmaceuticals logo

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.56 out of 5 stars

Medical Sector

504th out of 2,105 stocks

Pharmaceutical Preparations Industry

243rd out of 832 stocks

Analyst Opinion: 4.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions

Is Syndax Pharmaceuticals a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Syndax Pharmaceuticals stock.
View analyst ratings for Syndax Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Syndax Pharmaceuticals?

Wall Street analysts have given Syndax Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syndax Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Syndax Pharmaceuticals' next earnings date?

Syndax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Syndax Pharmaceuticals

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its earnings results on Tuesday, May, 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.09. The company had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.50 million. Syndax Pharmaceuticals had a negative net margin of 5,645.68% and a negative trailing twelve-month return on equity of 45.08%.
View Syndax Pharmaceuticals' earnings history

How has Syndax Pharmaceuticals' stock been impacted by COVID-19?

Syndax Pharmaceuticals' stock was trading at $11.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SNDX shares have increased by 49.7% and is now trading at $17.65.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SNDX?

9 brokers have issued twelve-month price objectives for Syndax Pharmaceuticals' shares. Their forecasts range from $20.00 to $32.00. On average, they expect Syndax Pharmaceuticals' stock price to reach $28.75 in the next year. This suggests a possible upside of 62.9% from the stock's current price.
View analysts' price targets for Syndax Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Syndax Pharmaceuticals' key executives?

Syndax Pharmaceuticals' management team includes the following people:
  • Dr. Briggs W. Morrison M.D., CEO & Director (Age 61, Pay $891.81k)
  • Mr. Michael A. Metzger, Pres, COO & Director (Age 50, Pay $856.78k)
  • Ms. Daphne Karydas M.B.A., Chief Financial Officer (Age 48, Pay $281.63k)
  • Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 52)
  • Dr. Richard A. Heyman, Co-Founder (Age 64)
  • Dr. Ronald M. Evans Ph.D., Co-Founder, Advisor and Chair of Scientific Advisory Board
  • Dr. Michael Downes Ph.D., Co-Founder
  • Mr. Luke J. Albrecht, Sr. VP, Gen. Counsel & Sec. (Age 42)
  • Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 70)
  • Dr. Edward A. Sausville M.D., Ph.D., Advisor

Who are some of Syndax Pharmaceuticals' key competitors?

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.55%), Nantahala Capital Management LLC (4.15%), PFM Health Sciences LP (3.08%), Frazier Management LLC (2.98%), Ghost Tree Capital LLC (2.44%) and Point72 Asset Management L.P. (1.96%). Company insiders that own Syndax Pharmaceuticals stock include Briggs Morrison, Dennis Podlesak, Michael A Metzger, Michael L Meyers and Peter Ordentlich.
View institutional ownership trends for Syndax Pharmaceuticals

Which major investors are selling Syndax Pharmaceuticals stock?

SNDX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Acuta Capital Partners LLC, Ikarian Capital LLC, Point72 Asset Management L.P., Ghost Tree Capital LLC, 683 Capital Management LLC, Sphera Funds Management LTD., and BNP Paribas Arbitrage SA. Company insiders that have sold Syndax Pharmaceuticals company stock in the last year include Michael A Metzger, and Peter Ordentlich.
View insider buying and selling activity for Syndax Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Syndax Pharmaceuticals stock?

SNDX stock was purchased by a variety of institutional investors in the last quarter, including PFM Health Sciences LP, BlackRock Inc., Vivo Capital LLC, Price T Rowe Associates Inc. MD, Putnam Investments LLC, Nantahala Capital Management LLC, Citigroup Inc., and Rafferty Asset Management LLC. Company insiders that have bought Syndax Pharmaceuticals stock in the last two years include Briggs Morrison, Dennis Podlesak, and Michael L Meyers.
View insider buying and selling activity for Syndax Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $17.65.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals has a market capitalization of $851.59 million and generates $1.52 million in revenue each year. The company earns $-73,160,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals employs 43 workers across the globe.

What is Syndax Pharmaceuticals' official website?

The official website for Syndax Pharmaceuticals is

Where are Syndax Pharmaceuticals' headquarters?

Syndax Pharmaceuticals is headquartered at 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]

This page was last updated on 6/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.